MBL Versus CLL. How Important Is the Distinction?

Lydia Scarfò, Claudia Fazi, Paolo Ghia

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Monoclonal B-cell lymphocytosis (MBL) is defined as a clonal B-cell expansion whereby the B-cell count is less than 5 × 109/L and no symptoms or signs of lymphoproliferative disorders are detected. Based on B-cell count, MBL is further divided into low-count and clinical MBL. While low-count MBL seems to carry relevance mostly from an immunological perspective, clinical MBL and chronic lymphocytic leukemia appear to be overlapping entities. Only a deeper knowledge of molecular pathways and microenvironmental influences involved in disease evolution will help to solve the main clinical issue, i.e. how to differentiate nonprogressive and progressive cases requiring intensive follow-up.

Original languageEnglish
Pages (from-to)251-265
Number of pages15
JournalHematology/Oncology Clinics of North America
Volume27
Issue number2
DOIs
Publication statusPublished - Apr 2013

Fingerprint

Lymphocytosis
B-Lymphocytes
Cell Count
Lymphoproliferative Disorders
B-Cell Chronic Lymphocytic Leukemia
Signs and Symptoms

Keywords

  • Chromosomal aberrations
  • Chronic lymphocytic leukemia
  • Immune system
  • Immunoglobulin genes
  • Immunophenotype
  • Monoclonal B-cell lymphocytosis
  • Prognosis
  • Progression

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

MBL Versus CLL. How Important Is the Distinction? / Scarfò, Lydia; Fazi, Claudia; Ghia, Paolo.

In: Hematology/Oncology Clinics of North America, Vol. 27, No. 2, 04.2013, p. 251-265.

Research output: Contribution to journalArticle

Scarfò, Lydia ; Fazi, Claudia ; Ghia, Paolo. / MBL Versus CLL. How Important Is the Distinction?. In: Hematology/Oncology Clinics of North America. 2013 ; Vol. 27, No. 2. pp. 251-265.
@article{ea2357739981444094299e28cfd44fcf,
title = "MBL Versus CLL. How Important Is the Distinction?",
abstract = "Monoclonal B-cell lymphocytosis (MBL) is defined as a clonal B-cell expansion whereby the B-cell count is less than 5 × 109/L and no symptoms or signs of lymphoproliferative disorders are detected. Based on B-cell count, MBL is further divided into low-count and clinical MBL. While low-count MBL seems to carry relevance mostly from an immunological perspective, clinical MBL and chronic lymphocytic leukemia appear to be overlapping entities. Only a deeper knowledge of molecular pathways and microenvironmental influences involved in disease evolution will help to solve the main clinical issue, i.e. how to differentiate nonprogressive and progressive cases requiring intensive follow-up.",
keywords = "Chromosomal aberrations, Chronic lymphocytic leukemia, Immune system, Immunoglobulin genes, Immunophenotype, Monoclonal B-cell lymphocytosis, Prognosis, Progression",
author = "Lydia Scarf{\`o} and Claudia Fazi and Paolo Ghia",
year = "2013",
month = "4",
doi = "10.1016/j.hoc.2013.01.004",
language = "English",
volume = "27",
pages = "251--265",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - MBL Versus CLL. How Important Is the Distinction?

AU - Scarfò, Lydia

AU - Fazi, Claudia

AU - Ghia, Paolo

PY - 2013/4

Y1 - 2013/4

N2 - Monoclonal B-cell lymphocytosis (MBL) is defined as a clonal B-cell expansion whereby the B-cell count is less than 5 × 109/L and no symptoms or signs of lymphoproliferative disorders are detected. Based on B-cell count, MBL is further divided into low-count and clinical MBL. While low-count MBL seems to carry relevance mostly from an immunological perspective, clinical MBL and chronic lymphocytic leukemia appear to be overlapping entities. Only a deeper knowledge of molecular pathways and microenvironmental influences involved in disease evolution will help to solve the main clinical issue, i.e. how to differentiate nonprogressive and progressive cases requiring intensive follow-up.

AB - Monoclonal B-cell lymphocytosis (MBL) is defined as a clonal B-cell expansion whereby the B-cell count is less than 5 × 109/L and no symptoms or signs of lymphoproliferative disorders are detected. Based on B-cell count, MBL is further divided into low-count and clinical MBL. While low-count MBL seems to carry relevance mostly from an immunological perspective, clinical MBL and chronic lymphocytic leukemia appear to be overlapping entities. Only a deeper knowledge of molecular pathways and microenvironmental influences involved in disease evolution will help to solve the main clinical issue, i.e. how to differentiate nonprogressive and progressive cases requiring intensive follow-up.

KW - Chromosomal aberrations

KW - Chronic lymphocytic leukemia

KW - Immune system

KW - Immunoglobulin genes

KW - Immunophenotype

KW - Monoclonal B-cell lymphocytosis

KW - Prognosis

KW - Progression

UR - http://www.scopus.com/inward/record.url?scp=84875773431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875773431&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2013.01.004

DO - 10.1016/j.hoc.2013.01.004

M3 - Article

C2 - 23561472

AN - SCOPUS:84875773431

VL - 27

SP - 251

EP - 265

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 2

ER -